Hard on the heels of a new $575 million partnership with GSK, US biotech SpringWorks Therapeutics has reported phase 3 data at ESMO that sets up regulatory filings for its lead drug nirogacestat ...

To access the live webcast, please visit the Events & Presentations page within the Investors & Media section of the ...

We recently compiled a list of the 12 NASDAQ Stocks with Biggest Upside Potential According to Analysts. In this article, we ...

Nov. 12, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer, today reported financial ...

J.P.  Morgan said its top biotech picks for 2025 were Vertex (NASDAQ:VRTX), Travere (NASDAQ:TVTX), SpringWorks (NASDAQ:SWTX), ...

SpringWorks will be led by a team of industry veterans including executive chairman Daniel Lynch, with more than 25 years of industry experience, and vice president of clinical R&D Mary Smith, who ...

When we last visited SpringWorks, the company was trying to get its primary drug candidate nirogacestat through the FDA approval process. Nirogacestat is an oral small-molecule gamma-secretase ...

SpringWorks Therapeutics, Inc. SWTX incurred a loss of 72 cents per share in the third quarter of 2024, which was narrower than the Zacks Consensus Estimate of a loss of 76 cents. The company had ...

STAMFORD, Conn., Nov. 26, 2024 (GLOBE NEWSWIRE) -- SpringWorks Therapeutics, Inc. (Nasdaq: SWTX), a commercial-stage biopharmaceutical company focused on severe rare diseases and cancer ...

SpringWorks Therapeutics (SWTX) announced that data from the pivotal, Phase 2b ReNeu trial of mirdametinib, an investigational MEK inhibitor, in adult and pediatric patients with neurofibromatosis ...